Salarius Pharmaceuticals Inc (NASDAQ:SLRX) is trading up in the pre-market session on Tuesday. The stock has been witnessing solid rally over the past 6-month with a jump 45%.
Market Reaction
As of 8:47, SLRX is up by 0.83% to $1.22 with 122K shares traded hands.
Major Trigger:
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
Key Highlights:
- today announced the initiation of a clinical trial to investigate seclidemstat, a novel lysine specific demethylase 1 (LSD1) inhibitor, as a potential treatment for hematologic cancers. This investigator-initiated Phase 1/2 trial will be led by Dr. Guillermo Montalban-Bravo from the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
- The trial will be an open label, dose-finding, dose-expansion study to determine the maximum tolerated dose (MTD) and the safety and tolerability of seclidemstat when used in combination with azacytidine as a treatment for Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). MDS and CMML are blood cancers that can progress into a deadly form of leukemia, Acute Myeloid Leukemia (AML).
- The trial was initiated because of compelling preclinical data in which seclidemstat demonstrated anti-proliferative activity across hematologic cancers and synergy when used in combination with azacytidine.
- Seclidemstat is a differentiated, oral, reversible inhibitor of LSD1, a key enzyme implicated in several cancer types. Seclidemstat is being studied in various solid tumor trials that have indicated seclidemstat has a manageable safety profile with preliminary evidence of anti-tumor activity.
 Announces New Data){kind=link}